The Crypto That’s Making Wall Street Sweat

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

R. Adams Biography and Net Worth

COO of Adaptive Biotechnologies

Mark Adams, PhD, is the Chief Operating Officer of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. Prior to joining Adaptive, Mark served as Managing Director, Healthcare Advanced Analytics, at SVB Leerink, a health and life sciences-focused investment bank, since April 2018. Mark has also served as Chief Information Officer at Celmatix, a women’s health precision medicine company, from September 2016 to April 2018, and at Good Start Genetics, a molecular diagnostics company. Mark holds a BA from Oberlin College and a PhD from Baylor College of Medicine.

What is R. Mark Adams' net worth?: The estimated net worth of R. Mark Adams is at least $785,296.98 as of April 10th, 2023. Dr. Adams owns 177,669 shares of Adaptive Biotechnologies stock worth more than $785,297 as of November 21st. This net worth approximation does not reflect any other assets that Dr. Adams may own. Learn More about R. Mark Adams' net worth.
How do I contact R. Mark Adams?: The corporate mailing address for Dr. Adams and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on R. Mark Adams' contact information.
Has R. Mark Adams been buying or selling shares of Adaptive Biotechnologies?: R. Mark Adams has not been actively trading shares of Adaptive Biotechnologies during the last ninety days. Most recently, R Mark Adams sold 817 shares of the business's stock in a transaction on Monday, April 10th. The shares were sold at an average price of $8.50, for a transaction totalling $6,944.50. Following the completion of the sale, the chief operating officer now directly owns 177,669 shares of the company's stock, valued at $1,510,186.50. Learn More on R. Mark Adams' trading history.
Who are Adaptive Biotechnologies' active insiders?: Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.
Are insiders buying or selling shares of Adaptive Biotechnologies?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 124,555 shares worth more than $429,325.41. The most recent insider tranaction occured on November, 18th when CFO Kyle Piskel sold 248 shares worth more than $1,235.04. Insiders at Adaptive Biotechnologies own 6.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.
Information on this page was last updated on 11/18/2024.

R. Mark Adams Insider Trading History at Adaptive Biotechnologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/10/2023	Sell	817	$8.50	$6,944.50	177,669
3/6/2023	Sell	6,529	$8.57	$55,953.53	195,641
1/9/2023	Sell	995	$8.50	$8,457.50	115,648
10/10/2022	Sell	2,284	$7.13	$16,284.92	116,643
10/7/2022	Sell	841	$7.61	$6,400.01	118,927
7/7/2022	Sell	825	$9.53	$7,862.25	122,068
4/7/2022	Sell	831	$13.17	$10,944.27	122,893
3/7/2022	Sell	1,244	$12.01	$14,940.44
10/7/2021	Sell	1,324	$32.47	$42,990.28
7/7/2021	Sell	871	$39.42	$34,334.82
6/17/2021	Sell	14,583	$40.00	$583,320.00	72,687
6/14/2021	Sell	8,914	$38.77	$345,595.78	58,104
4/7/2021	Sell	3,586	$42.34	$151,831.24	67,018

R. Mark Adams Buying and Selling Activity at Adaptive Biotechnologies

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Today's Range

Now: $4.42

$4.33

$4.57

50 Day Range

MA: $4.96

$4.00

$6.49

2 Week Range

Now: $4.42

$2.28

$6.70

Volume

1,819,296 shs

Average Volume

1,409,831 shs

Market Capitalization

$652.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45